Quizartinib therapeutic targets and mechanisms of action

Quizartinib is an oral kinase inhibitor indicated for the treatment of patients with **FLT3-ITD-positive acute myeloid leukemia (AML)**. AML is a malignant tumor derived from bone marrow. About 30% to 35% of patients have FLT3 gene mutations, among which FLT3-ITD mutations are particularly common. This mutation leads to overactivation of the FLT3 receptor, which in turn causes excessive proliferation and survival of leukemia cells.

Quizatinib effectively inhibits the growth of leukemia cells by specifically inhibiting the tyrosine kinase activity ofFLT3 and blocking abnormal signal transduction. The FLT3 receptor belongs to the tyrosine kinase family, and under normal circumstances, it is involved in regulating the proliferation and differentiation of hematopoietic cells. However, mutations in the FLT3 gene, especially **FLT3 internal tandem duplication (ITD)** mutations, can lead to abnormal activation of the receptor, thereby promoting the disordered proliferation of leukemia cells. By targeting this mutation, Quizartinib precisely inhibits the overactivation of FLT3 and inhibits the proliferation of leukemia cells.

Clinical studies have shown that quizartinib has a significant therapeutic effect on AML patients with FLT3-ITD mutations, especially those who still have disease progression after receiving multiple conventional treatments. Quizartinib can not only be used in combination with traditional chemotherapy drugs such as cytarabine, but can also be used as consolidation therapy to maintain the efficacy, thereby significantly improving the survival rate of patients.

Quizatinib’s targeting effect makes it have a lower risk of side effects when treatingAML. It is less toxic than traditional chemotherapy drugs and also has a certain inhibitory effect on other types of FLT3 mutations. This feature makes quizartinib a promising drug for the treatment of FLT3-ITD-positive AML. The correct taking method is crucial to ensure the therapeutic effect. Patients should strictly follow the doctor's instructions and conduct regular review according to the doctor's instructions to ensure the safety and effectiveness of the treatment.

Keyword tags: Quizartinib,Quizartinib, FLT3-ITD, acute myeloid leukemia, AML, tyrosine kinase, targeted therapy, treatment mechanism, leukemia

References:https://en.wikipedia.org/wiki/Quizartinib